Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

INSTI, tenofovir-free single-tablet maintenance option for virologically suppressed adults, expanding choices beyond ...

Integrating GLP-1 therapy into primary care enables clinicians to contextualize weight loss alongside cardiometabolic ...

In March, Pharmaceutical Executive reported on Eli Lilly’s efforts to push back against the availability of compounded GLP-1 ...

IV fluids like normal saline, dextrose, and sterile water are the most systemically dangerous shortages on the list, as they ...

Documented AI productivity gains include 28% faster target identification, 22% faster biomarker identification, and 20% ...

The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...

CEO of MaxCyte, discusses the need for developers to come together with platforms. Advertisement. Latest Updated Articles. Advertisement ...

In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected ...